TP53 mutations are also found in 20–27% of AML with myelodysplasia-related changes (AML-MRC) and up to 40% of therapy-related AML myelodysplastic syndrome (AML/MDS) [50]. This evidence concerns the gene TP53 and myelodysplastic syndrome.